Notice of Proposed Sale · 144
NewAmsterdam Pharma Company N.V.
NAMSNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- NewAmsterdam Pharma Company N.V.
- Issuer CIK
- 0001936258
- SEC file number
- 001-41562
- Phone
- 31-0-35-206-2971
- Person for whose account securities are to be sold
- Kastelein Johannes Jacob Pieter
- Relationships to issuer
- Affiliate
- Street
- Gooimeer 2-35
- City
- DC Naarden
- State / country code
- P7
- Postal code
- 1411
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Ordinary Shares | 125,000 | 3,483,750 | 119,537,169 | 08/24/2026 | Nasdaq | J.P. Morgan Securities LLC |
Broker / market maker — proposed row 1, entry 1
- Name
- J.P. Morgan Securities LLC
- Street
- 270 Park Avenue - 10th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10017
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | 08/24/2026 | Option Exercise | Issuer | 125,000 | N | 08/24/2026 | Cash |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Remarks
The shares represented on this filing are for shares expected to be sold in the next 90 days by Futurum B.V., John Kastelein as Director
Notice signature
- Notice date
- 08/24/2026
- Signed
- /s/ J.P. Morgan Securities LLC as agent and attorney-in-fact for Michael H. Davidson
- Plan adoption dates
- 05/28/2026
Company context
NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company dedicated to building a new standard of care for people living with cardiometabolic and neurodegenerative diseases. The Company is advancing therapies designed to address a significant unmet need for safe, well-tolerated, and convenient treatment options that lower LDL-C while advancing innovation beyond a single marker to better address cardiovascular risk. In multiple Phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose, once-daily CETP inhibitor, alone and as a fixed-dose combination with ezetimibe, in patients at risk of cardiovascular disease with elevated LDL-C. Guided by its mission, the Company challenges convention with courage, translates deep biological insight into meaningful patient impact, and delivers with rigor, precision, and purpose.